Investors are anticipating that UCITS III funds will receive more than USD185bn in inflows over the next year, according to a recent survey by Deutsche Bank. Having had a UCITS III Long/SHort equity fund available since 2007, plus several new UCITS III hedge fund strategies in the pipeline, Salus Alpha is well placed to benefit from what could be a doubling in size of the sector over the next year.
“We started the wave of UCITS III hedge funds since we have been the first one to launch a UCITS III Long/Short Equity fund in 2007. When lobbying towards CESR (now ESMA) to expand the eligible asset directive to include hedge fund indices and hedge fund strategy indices we had no idea what we triggered”, says Oliver Prock, CEO of Salus Alpha.
"This year we will strengthen our world leader status by extending our product range with several new UCITS III hedge funds strategies, i.e. Fixed Income Arbitrage, Credit Arbitrage, Long/Short Emerging Market and Alpha Replication which brings us to a total of 12 UCITS III hedge funds of which 8 are in-house managed Single Manager Products. Our business strategy i.e. to offer all hedge fund strategies in a UCITS III format with daily liquidity confirms investor’s demand.
"Non-European investors now view UCITS III as a high quality global brand, and UCITS funds are increasingly seeing interest from investors in Hong Kong, Singapore, Dubai, US and other emerging markets. Salus Alpha is also well positioned to promote UCITS funds outside Europe through in-house distribution capabilities but is also looking actively for distribution partners globally."
